Szliszka et al. reported the potential of combined therapy using tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and PDT to induce cytotoxicity in bladder cancer cells [24]. This evidence concerns the gene TNFSF10 and urinary bladder cancer.